View Item 

Show simple item record

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorBolejack, Vanessa
dc.contributor.authorChoy, Edwin
dc.contributor.authorGanjoo, Kristen N.
dc.contributor.authorStaddon, Arthur P.
dc.contributor.authorChow, Warren A.
dc.contributor.authorTawbi, Hussein A.
dc.contributor.authorSamuels, Brian L.
dc.contributor.authorPatel, Shreyaskumar R.
dc.contributor.authorMehren, Margaret
dc.contributor.authorD’Amato, Gina
dc.contributor.authorLeu, Kirsten M.
dc.contributor.authorLoeb, David M.
dc.contributor.authorForscher, Charles A.
dc.contributor.authorMilhem, Mohammed M.
dc.contributor.authorRushing, Daniel A.
dc.contributor.authorLucas, David R.
dc.contributor.authorChugh, Rashmi
dc.contributor.authorReinke, Denise K.
dc.contributor.authorBaker, Laurence H.
dc.date.accessioned2017-01-10T19:03:29Z
dc.date.available2018-03-01T16:43:50Zen
dc.date.issued2017-01-01
dc.identifier.citationSchuetze, Scott M.; Bolejack, Vanessa; Choy, Edwin; Ganjoo, Kristen N.; Staddon, Arthur P.; Chow, Warren A.; Tawbi, Hussein A.; Samuels, Brian L.; Patel, Shreyaskumar R.; Mehren, Margaret; D’Amato, Gina; Leu, Kirsten M.; Loeb, David M.; Forscher, Charles A.; Milhem, Mohammed M.; Rushing, Daniel A.; Lucas, David R.; Chugh, Rashmi; Reinke, Denise K.; Baker, Laurence H. (2017). "Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor." Cancer 123(1): 90-97.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/135187
dc.publisherWiley Periodicals, Inc.
dc.publisherInternational Agency for Research on Cancer
dc.subject.otherdasatinib
dc.subject.otherphase 2
dc.subject.othersarcoma
dc.subject.otherchondrosarcoma
dc.subject.otherChoi
dc.subject.otherchemotherapy
dc.subject.otherBayesian
dc.subject.otherchordoma
dc.titlePhase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135187/1/cncr30379_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135187/2/cncr30379.pdf
dc.identifier.doi10.1002/cncr.30379
dc.identifier.sourceCancer
dc.identifier.citedreferenceStacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012; 23: 3171 – 3179.
dc.identifier.citedreferenceYamada Y, Kohashi K, Fushimi F, et al. Activation of the Akt‐mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Cancer. 2014; 120: 864 – 876.
dc.identifier.citedreferenceHindi N, Casali PG, Morosi C, et al. Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer. 2015; 51: 2609 – 2614.
dc.identifier.citedreferenceItaliano A, Le Cesne A, Bellera C, et al. GDC‐0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute single‐arm phase II collaborative study. Ann Oncol. 2013; 24: 2922 – 2926.
dc.identifier.citedreferenceChugh R, Dunn R, Zalupski MM, et al. Phase II study of 9‐nitro‐camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005; 23: 3597 – 3604.
dc.identifier.citedreferenceFletcher CD, Bridge JA, Hogendoorn PC, Mertens F. WHO classification of tumours of soft tissue and bone. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H, eds. World Health Organization Classification of Tumours. Lyon, France: International Agency for Research on Cancer; 2013: 468.
dc.identifier.citedreferenceChoi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753 – 1759.
dc.identifier.citedreferenceDemetri GD, Lo Russo P, MacPherson IR, et al. Phase I dose‐escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009; 15: 6232 – 6240.
dc.identifier.citedreferenceSchuetze SM, Wathen JK, Lucas DR, et al. SARC009: phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma. Cancer. 2016; 122: 868 – 874.
dc.identifier.citedreferenceKantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260 – 2270.
dc.identifier.citedreferencevan Oosterwijk JG, van Ruler MA, Briaire‐de Bruijn IH, et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer. 2013; 109: 1214 – 1222.
dc.identifier.citedreferenceSchrage YM, Briaire‐de Bruijn IH, de Miranda NF, et al. Kinome profiling of chondrosarcoma reveals SRC‐pathway activity and dasatinib as option for treatment. Cancer Res. 2009; 69: 6216 – 6222.
dc.identifier.citedreferenceAkhavan‐Sigari R, Gaab MR, Rohde V, Abili M, Ostertag H. Expression of PDGFR‐alpha, EGFR and c‐MET in spinal chordoma: a series of 52 patients. Anticancer Res. 2014; 34: 623 – 630.
dc.identifier.citedreferenceLee DH, Zhang Y, Kassam AB, et al. Combined PDGFR and HDAC inhibition overcomes PTEN disruption in chordoma. PLoS One. 2015; 10: e0134426.
dc.identifier.citedreferencePennacchioli E, Fiore M, Collini P, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol. 2010; 17: 3229 – 3233.
dc.identifier.citedreferencePortera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001; 91: 585 – 591.
dc.identifier.citedreferenceSpitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW. Hemangiopericytoma: a 20‐year single‐institution experience. Ann Surg Oncol. 1998; 5: 350 – 355.
dc.identifier.citedreferenceGuzzetta AA, Montgomery EA, Lyu H, et al. Epithelioid sarcoma: one institution’s experience with a rare sarcoma. J Surg Res. 2012; 177: 116 – 122.
dc.identifier.citedreferenceStacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011; 22: 1682 – 1690.
dc.identifier.citedreferenceKummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013; 31: 2296 – 2302.
dc.identifier.citedreferencePark MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011; 117: 4939 – 4947.
dc.identifier.citedreferenceStacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012; 30: 914 – 920.
dc.identifier.citedreferencePink D, Richter S, Gerdes S, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi‐institutional analysis. Oncology. 2014; 87: 95 – 103.
dc.identifier.citedreferenceJones RL, Constantinidou A, Olmos D, et al. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012; 35: 351 – 357.
dc.identifier.citedreferenceJawad MU, Extein J, Min ES, Scully SP. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res. 2009; 467: 2939 – 2948.
dc.identifier.citedreferenceStacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR‐positive chordoma. Ann Oncol. 2013; 24: 1931 – 1936.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30379_am.pdf
Size:
393.0KB
Format:
PDF
View/Open
Name:
cncr30379.pdf
Size:
170.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.